[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Abbvie Inc (ABBV)

Abbvie Inc (ABBV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 356,374,432
  • Shares Outstanding, K 1,768,169
  • Annual Sales, $ 61,160 M
  • Annual Income, $ 4,226 M
  • EBIT $ 15,332 M
  • EBITDA $ 24,318 M
  • 60-Month Beta 0.32
  • Price/Sales 5.86
  • Price/Cash Flow 13.38
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 27.62% (+0.82%)
  • Historical Volatility 25.44%
  • IV Percentile 56%
  • IV Rank 54.38%
  • IV High 35.30% on 04/27/26
  • IV Low 18.46% on 08/22/25
  • Expected Move (DTE 5) 5.13 (2.54%)
  • Put/Call Vol Ratio 1.15
  • Today's Volume 15,468
  • Volume Avg (30-Day) 16,519
  • Put/Call OI Ratio 1.11
  • Today's Open Interest 268,817
  • Open Int (30-Day) 249,849
  • Expected Range 196.42 to 206.68

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 32 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $3.73
  • Number of Estimates 9
  • High Estimate $3.93
  • Low Estimate $3.50
  • Prior Year $2.97
  • Growth Rate Est. (year over year) +25.59%

Price Performance

See More
Period Period Low Period High Performance
1-Month
190.75 +5.66%
on 04/29/26
214.87 -6.20%
on 04/30/26
-10.04 (-4.75%)
since 04/08/26
3-Month
190.75 +5.66%
on 04/29/26
237.11 -15.00%
on 03/04/26
-21.88 (-9.79%)
since 02/06/26
52-Week
176.57 +14.15%
on 05/15/25
244.81 -17.67%
on 10/01/25
+15.97 (+8.61%)
since 05/08/25

Most Recent Stories

More News
AbbVie Touts Record Sales and Pipeline Momentum at Annual Meeting

AbbVie (NYSE:ABBV) told shareholders at its annual meeting that 2025 was “another excellent year” for the company, citing record sales, stronger-than-expected revenue and continued investment in its...

ABBV : 201.55 (-0.57%)
AbbVie Delivers Strong Q1 Earnings Beyond Humira. This Dividend King Still Shines.

Q1 earnings show this Dividend King still looks built for the long term.

ABBV : 201.55 (-0.57%)
AbbVie to Present at the Bank of America Securities Healthcare Conference

NORTH CHICAGO, Ill. , May 6, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Bank of America Securities Healthcare Conference on Wednesday, May 13, 2026. Management will participate...

ABBV : 201.55 (-0.57%)
5 Must-Read Analyst Questions From AbbVie’s Q1 Earnings Call

5 Must-Read Analyst Questions From AbbVie’s Q1 Earnings Call

ABBV : 201.55 (-0.57%)
AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®

NORTH CHICAGO, Ill. , May 5, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the presentation of new data across its gastroenterology portfolio at the 2026 Digestive Disease Week (DDW)...

ABBV : 201.55 (-0.57%)
The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the Beat

Big Pharma stalwarts AbbVie, AstraZeneca, and GSK beat Q1 revenue expectations, raising guidance and offering a potential tailwind for the flailing medical sector.

AZN : 182.85 (+0.18%)
ABBV : 201.55 (-0.57%)
GSK : 50.41 (-0.18%)
MarketBeat Week in Review – 04/27 - 05/01

Sell in May and go away may not be the right strategy after stocks closed out a strong April and strong earnings point to more gains

MXL : 99.83 (+21.20%)
GOOGL : 400.80 (+0.71%)
AAPL : 293.32 (+2.05%)
VZ : 47.22 (+0.28%)
CVX : 181.62 (-0.48%)
TTD : 23.08 (-1.75%)
FOUR : 42.58 (-9.11%)
REAX : 2.04 (-8.52%)
DPZ : 323.48 (-2.72%)
GLW : 186.94 (+2.49%)
RMAX : 10.38 (-6.15%)
QCOM : 219.09 (+8.17%)
AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec

National competition, in collaboration with adMare BioInnovations, demonstrates AbbVie's commitment to a thriving biotech ecosystem in Quebec. Award provides RIME Therapeutics with a year of laboratory...

ABBV : 201.55 (-0.57%)
Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month

IRVINE, Calif. , April 30, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, today announced a charitable initiative in recognition of Skin Cancer Awareness Month. Throughout...

ABBV : 201.55 (-0.57%)
ABBV Q1 Deep Dive: Immunology and Neuroscience Growth, Raised Full-Year Outlook

ABBV Q1 Deep Dive: Immunology and Neuroscience Growth, Raised Full-Year Outlook

ABBV : 201.55 (-0.57%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi...

See More

Key Turning Points

3rd Resistance Point 205.01
2nd Resistance Point 203.70
1st Resistance Point 202.63
Last Price 201.55
1st Support Level 200.25
2nd Support Level 198.94
3rd Support Level 197.87

See More

52-Week High 244.81
Fibonacci 61.8% 218.74
Fibonacci 50% 210.69
Fibonacci 38.2% 202.64
Last Price 201.55
52-Week Low 176.57

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.